That would have been very helpful. 104 would have been a $B drug almost immediately if it had gotten favorable scheduling. The key now is the labeling. If the language in the PPI is allowed to claim less abuse potential and decreased risk of OD it will still be a considerable advantage over current stimulants. Another consideration is that patients on 104 have indicated that the actual delivery of the medication to the system is smoother and longer acting as well which is another marketable advantage. The key is Shire's ability to market to the specialty physician and thier relationship with them. Shire is trusted in this market and physicians will listen when they approach them about the switch.